Hims & Hers Health has launched a generic version of semaglutide for Canadians with type 2 diabetes. This product, available through their telehealth platform, is a significant step in providing affordable healthcare options. The drug is produced by Apotex Inc., the largest Canada-based global health company.
Innovative Generic Launch
The introduction of Apo-Semaglutide Injection marks Hims’s first international generic offering in the GLP-1 drug sector. This comes after the expiration of Novo Nordisk’s patent on semaglutide, which previously prevented other companies from selling similar products. With this patent now expired, additional manufacturers are looking to enter the Canadian market.
Approval and Availability
Health Canada approved Apotex’s semaglutide earlier this month. The generic version is specifically indicated for weekly treatment of adults with type 2 diabetes. This approval allows Hims to provide Canadians with a more economical alternative to the branded drug Ozempic, which is priced between $200 and $400 per month based on factors like dosage and insurance coverage.
Market Impact
Sandy Van, the chief medical officer at Hims & Hers Canada, emphasized the benefits of having more affordable options. “When more affordable options enter the GLP-1 space, it becomes more dynamic, and prices fall across the board,” she stated. This development is expected to positively impact patients seeking care across Canada.
Future Collaborations
Hims has indicated that it is open to partnering with other manufacturers in Canada to expand access to these medications. Currently, personalized treatment plans through Hims’s platform start at $149 per month, providing a cost-effective solution for those managing type 2 diabetes.
- Product: Apo-Semaglutide Injection
- Manufacturer: Apotex Inc.
- Approval Date: Earlier this month
- Price Range for Ozempic: $200 – $400 per month
- Hims Plan Starting Price: $149 per month
This launch marks a significant shift in the availability of diabetes treatments in Canada, aimed at improving patient outcomes and making essential medications more accessible.
